---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-089137"
form_type: "8-K"
ticker: "NKTR"
cik: "0000906709"
company_name: "NEKTAR THERAPEUTICS"
filed_at: "2026-08-13T20:25:23+00:00"
generated_at: "2026-08-13T20:26:43.175550+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Nektar Q2 2026: cash $1.02B, net loss $40.6M, Phase 3 ZENITH AD initiated

## Summary
- Cash and investments $1,023.4M at June 30, 2026 vs $245.8M at Dec 31, 2025; runway into Q3 2028.
- Q2 revenue $10.1M (vs $11.2M); net loss $40.6M ($1.23/share) vs $41.6M ($2.95/share) year-ago.
- R&D expense $39.1M (up from $29.9M) on Phase 3 ZENITH AD and manufacturing; G&A down to $12.8M.
- Initiated first two Phase 3 ZENITH AD trials in atopic dermatitis in July 2026; BLA submission planned 2029.
- April 2026 offering raised $373.8M gross; positive 52-week REZOLVE-AA results announced.

## SEC filing metadata
- accession: 0001213900-26-089137
- form_type: 8-K
- ticker: NKTR
- cik: 0000906709
- company_name: NEKTAR THERAPEUTICS
- filed_at: 2026-08-13T20:25:23+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/906709/000121390026089137/0001213900-26-089137-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/906709/000121390026089137/ea0301929-8k_nektar.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-089137
- JSON: https://secwatch.observer/filing/0001213900-26-089137.json
- Plain text: https://secwatch.observer/filing/0001213900-26-089137.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.